

2004 Asilomar Plenary Session Titles:

<u>Speaker</u>	<u>Presentation Title</u>
Jerry Rice	<u>Recent Science & Ethics Review Panel Activity</u> <i>Updating external review panel activities since last year's Asilomar conference... feedback on study progress, protocol changes, and recruitment of two new bioethicists</i>
Fu Hua	<u>Building Institutional Relationships through the Shanghai Health Study</u> <i>Update of organizational relationships in Shanghai, one year into data collection, with focus on Clinical Lab and Principal Investigator relationships with (and benefits to) Fudan University and the 27 allied hospitals.</i>
You-Xin Liang	<u>QA/QC Approaches in Shanghai Health Study</u> <i>Application of quality assurance & quality control (QA/QC) to disparate activities – exposure fieldwork, clinical laboratory analyses, and server-based data management – in CC, DP & ME studies (You-Xin now heads QA/QC assurance for the Shanghai Health Study).</i>
Otto Wong	<u>Case-control study of AML and NHL in Shanghai</u> <i>Overview & progress of CC study after 'a year of case accrual', highlighting issues in control selection process and in exposure reconstruction.</i>
Robert Schnatter	<u>Molecular Epidemiology Studies in Shanghai</u> <i>Overview & progress of ME study, highlighting ethical, political and regulatory issues in factory participation with quantitative documentation of 'worker overexposure' in Shanghai.</i>
Tom Armstrong	<u>A Butcher, a Baker, a Candlestick Maker: An Overview of Jobs and Exposures in the Shanghai Studies</u> <i>Exposure assessment and reconstruction for workers with different job classifications and within the same occupation in Shanghai</i>
Richard Irons	<u>Shanghai Health Study - Clinical Aspects</u> <i>Overview of DP & ME studies, with progress and issues updated after a year of case referrals to the new Clinical lab, highlighting clinical aspects of the study.</i>

{ DATE \@ "M/d/yyyy" }

SHANGHAI HEALTH STUDY

ANNUAL MEETING 17-19 AUGUST 2004

DAY 1 – Tuesday, August 17

Morning / Afternoon

4:00 PM – 7:00 PM

5:30 PM – 6:30 PM

6:30 PM – 8:30 PM

Comments

Travel

Registration
(Phoebe A. Hearst Social Hall)

Reception (Seascape)

Dinner (Seascape)

DAY 2 – Wednesday, August 18

7:30 AM - 8:30 AM

Breakfast (dining room)

8:30 AM - 2:30 PM

Plenary Session (Chapel)
Co-Chairs: Patsy Clegg and Patrick Beatty

8:30 AM

Welcome and Introduction

Patsy Clegg (Shell)

Chair, Benzene Health Research Consortium Oversight Committee

Dr. Patrick Beatty, Ph.D. (ChevronTexaco)

Chair, Benzene Health Research Consortium Technical Committee

8:45 AM

Scientific Review Panel Activities

Dr. Jerry Rice, Ph.D. (International Agency for Research on Cancer, retired)

Chair, Scientific Review Panel

Ethics Review Panel Activities

TBD

Chair, Ethics Review Panel

9:15 AM

Dr. Fu Hua, MB, MPH, Ph.D. (Fudan University School of Public Health)

9:45 AM

Case Control Study of AML and NHL in Shanghai

Dr. Otto Wong, Sc.D. (Applied Health Sciences)

10:15 AM

Tom Armstrong (ExxonMobil Biomedical Sciences)

10:45 AM

Break

11:00 AM

Dr. Robert Schnatter, Ph.D. (ExxonMobil Biomedical Sciences)

Asilomar Conference Center ♦ 831/372-8016 ♦ Monterey Peninsula ♦ CA

SHELL-MCCLURG-065336

SHANGHAI HEALTH STUDY

ANNUAL MEETING 17-19 AUGUST 2004

11:30 AM **Dr. Liang You-xin, MD (Fudan University School of Public Health)**

12:00 PM Lunch (dining room)

1:00 PM – **Clinical and Molecular Laboratory**
2:30 PM Dr. Richard Irons, Ph.D. (University of Colorado)

2:45 PM – 5:00 PM Panel Meetings (Sanderling)

2:45 PM **Ethics Review Panel (ERP) Meeting** (*closed attendance*)

3:45 PM Break

4:00 PM **Scientific Review Panel (SRP) Meeting** (*closed attendance*)

6:00 PM Dinner (Barbeque Pit)

DAY 3 – Thursday, August 19

7:30 AM - 8:30 AM Breakfast (dining room)

9:00 AM **Joint Panel / Investigator Meeting** (*closed attendance in Sanderling*)
Ethics Review Panel / Scientific Review Panel / Principal Investigators

10:00 AM Break

10:30 AM **Joint Panel / Investigator Meeting continued** (*closed attendance in Sanderling*)
Ethics Review Panel / Scientific Review Panel / Principal Investigators

12:00 PM Lunch (dining room)

1:00 PM **Plenary Session** (*Chapel*)

2:30 PM **Annual Meeting Adjourned**

SHANGHAI HEALTH STUDY

ANNUAL MEETING 17-19 AUGUST 2004

6:00 PM

Dinner (dining room)

DAY 4 – Friday, August 20

Depart

SHANGHAI HEALTH STUDY

ANNUAL MEETING 17 - 19 AUGUST 2004

RESERVATION / REGISTRATION REQUEST

Title _____

First Name: : Patsy _____

Last Name: Clegg _____

Name for Badge: Patsy Clegg _____

Company or Affiliation: Shell Chemicals _____

Address: 910 Louisiana St Houston, TX 77002 _____

Phone: __713-241-2521_____ Fax: 713-241-3325 _____

Email: patsy.clegg@shell.com _____

ACCOMMODATIONS:

 x I / We plan to stay at Asilomar; please reserve a room.*

I will arrive on: __Tues, Aug 17_____ Depart on: Fri Aug 20 _____

 I / We do not plan to stay at Asilomar and will make our own reservations.

ADDITIONAL GUESTS:

First and Last Name: J.R. Clegg _____

(If you have children accompanying you, please supply their age)

SPECIAL EVENTS:

Yes / No I / We will attend the Welcome Reception and dinner (Tuesday evening, Aug. 17th)
(# of adults 2 # of children)

Yes / No I / We will attend the Cookout (Wednesday evening, Aug. 18th):
(# of adults 2 # of children)

I (have / do not have) special needs. Please let us know how we can assist.

Please email to toddm@api.org or fax to Matthew Todd at 202-682-8031 no later than April 15th.

* - Asilomar reservations are for August 17-19, 2004. Due to the Asilomar reservation policy, once you agree to reserve a room you will be responsible for payment even if you do not attend the meetings.

2004 SHANGHAI HEALTH STUDY ANNUAL MEETING ATTENDEES

Name	Company / Organization	Study Role	E-Mail	Phone
Fu Hua	Fudan University	Investigator	hfu@shmu.edu.cn	86 21 64041900
Liang You-Xin	Fudan University	Investigator	yxliang@shmu.edu.cn	86 21 64043069
Rob Schnatter	ExxonMobil Biomedical Sciences	Investigator	a.r.schnatter@exxonmobil.com	908-730-1101
Otto Wong	Applied Health Sciences	Investigator	ottowong@aol.com	650-347-7898
Rich Irons	University of Colorado	Investigator	richard.iron@uchsc.edu	303-315-7196
Yimei Zhou	ExxonMobil	Investigator	yimei.x.zhou@exxonmobil.com	
Dick Albertini	University of Vermont	Scientific Review Panel	ralbert315@aol.com	802-656-8346
Harvey Checkoway	University of Washington	Scientific Review Panel	checko@u.washington.edu	206-543-2052
John Cherrie	Institute of Occupational Medicine	Scientific Review Panel	john.cherrie@iomhg.org.uk	44 0131 449 8032
Helmut Greim	Technical University of Munich	Scientific Review Panel	helmut.greim@lrz.tum.de	49 8161 715 600
Rich Larson	University of Chicago	Scientific Review Panel	rlarson@medicine.bsd.uchicago.edu	773 702-6783
Li Guilan	Chinese Center of Disease Control and Prevention	Scientific Review Panel	guilanli@263.net.cn	86 10 83132900
Jerry Rice	Georgetown University Medical Center	Scientific Review Panel	jmricewas@aol.com	202-986-0659
Howard Rockette	University of Pittsburgh	Scientific Review Panel	herbst@pitt.edu	412 624-3023
Juhanna Idanpaan-Heikkila	Council for Int'l Organization of Medical Sciences (CIOMS)	Ethics Review Panel	juhana.idanpaan@pp.fimnet.fi idanpaan@who.int	
Xu Zongliang	Center for Applied Ethics	Ethics Review Panel	xzllzx@citiz.net	86 021 65643040
Liang Zhengliu	Guest	Ethics Review Panel (translator)	zhengliuliang@hotmail.com	
Ellen Clayton	Vanderbilt University	Ethics Review Panel	ellen.w.clayton@vanderbilt.edu	615-322-1186
Paul Lombardo	University of Virginia	Ethics Review Panel	pal8g@virginia.edu	434-982-4227
Mike Johnston	ConocoPhillips	Sponsor - Oversight	mike.d.johnston@conocophillips.com	703 846-1199
Patsy Clegg	Shell Chemical	Sponsor - Oversight	patsy.clegg@shell.com	713-241-2521
Don Burnett	BP	Sponsor - Oversight	burnettdm@bp.com	630-420-5093
Brian Doll	ExxonMobil	Sponsor - Oversight	brian.e.doll@exxonmobil.com	703-846-2515
Patrick Beatty	ChevronTexaco	Sponsor - Technical	patrickbeatty@chevrontexaco.com	510 242-7037
Stuart Cagen	Shell Chemical	Sponsor - Technical	stuart.cagen@shell.com	713-241-1407
Michael Bird	ExxonMobil	Sponsor - Technical	michael.g.bird@exxonmobil.com	908-730-1060
Shan Tsai	Shell Oil	Sponsor - Technical	shan.tsai@shell.com	713-241-6078
Chris Roythorne	BP	Sponsor - Technical	chris.roythorne@uk.bp.com	207 496-4634
Lynn Russo	ExxonMobil	Sponsor - Communications	lynn.b.russo@exxonmobil.com	703-846-2500
Camille Costello	ChevronTexaco	Sponsor - Communications	ccaj@chevrontexaco.com	925-842-2583
Laurie Labuda	APCO	Communications	llabuda@apcoworldwide.com	202-659-7903
Geoff Granville	Shell Canada	Sponsor	geoffrey.granville@shell.com	403-691-2220
Lorraine Twerdok	API	Administrator - Oversight	twerdokl@api.org	202-682-8344
Bruce Jarnot	API	Administrator - Technical	jarnotb@api.org	202-682-8473
Matt Todd	API	Administrator - Communications	toddm@api.org	202-682-8319
Madeleine Sellouk	API	Administrator - Meetings	selloukm@api.org	202-682-8332

2004 SHANGHAI HEALTH STUDY ANNUAL MEETING ATTENDEES

	A	B	C	D	E	F	G
1	2004 SHS Annual Meeting Attendees						
2							
3							
4		email invite sent	email registration sent	hard copy invite sent	hard copy registration sent	registration received	
5	Oversight						
6	Mike Johnston	3/25/2004	3/25/2004	NA	NA	3/29/2004	1
7	Patsy Clegg	3/25/2004	3/25/2004	NA	NA	4/1/2004	1
8	Patrick Beatty	3/25/2004	3/25/2004	NA	NA	3/30/2004	1
9	Don Burnett	3/25/2004	3/25/2004	NA	NA	4/8/2004	1
10	Brian Doll	3/25/2004	3/25/2004	NA	NA	5/10/2004	1
11							
12	Communications						
13	Camille Costello	3/25/2004	3/25/2004	NA	NA	6/22/2004	1
14	Lynn Russo	3/25/2004	3/25/2004	NA	NA	4/16/2004	1
15							
16	Technical						
17	Chris Roythorne	3/25/2004	3/25/2004	NA	NA	3/26/2004	1
18	Stu Cagen	3/25/2004	3/25/2004	NA	NA	4/14/2004	1
19	Michael Bird	3/25/2004	3/25/2004	NA	NA	4/15/2004	1
20	Shan Tsai	3/25/2004	3/25/2004	NA	NA	4/15/2004	1
21	Jennifer Galvin	3/26/2004	3/26/2004	NA	NA	4/14/2004	1
22							
23	SRP						
24	Dick Albertini	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/12/2004	1
25	Harvey Checkoway	3/25/2004	3/25/2004	3/25/2004	3/25/2004	3/29/2004	1
26	John Cherrie	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/23/2004	1
27	Helmut Greim	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/1/2004	1
28	Robert Herrick	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/21/2004	1
29	Richard Larson	3/25/2004	3/25/2004	3/25/2004	3/25/2004	3/30/2004	1
30	Guilan Li	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/27/2004	1
31	Mark Minden	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/27/2004	1
32	Jerry Rice	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/3/2004	1
33	Howard Rockette	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/19/2004	1
34							
35	ERP						
36	Juhana Idanpaan-Heikkila	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/21/2004	1
37	Zongliang Xu	3/25/2004	3/25/2004	3/25/2004	3/25/2004	4/26/2004	1
38	Zhengliu Liang (translator)	5/3/2004	5/3/2004	5/3/2004	5/3/2004	6/17/2004	1
39	Ellen Clayton	5/3/2004	5/3/2004	5/3/2004	5/3/2004	5/24/2004	1
40	Paul Lombardo	5/3/2004	5/3/2004	5/3/2004	5/3/2004	5/3/2004	1
41							

	A	B	C	D	E	F	G
42	PI US						
43	Rob Schnatter	4/7/2004	4/7/2004	4/8/2004	4/8/2004	4/15/2004	1
44	Otto Wong	4/7/2004	4/7/2004	4/8/2004	4/8/2004	4/22/2004	1
45	Rich Irons	4/7/2004	4/7/2004	4/8/2004	4/8/2004	ATTENDING	1
46	Tom Armstrong	4/7/2004	4/7/2004	4/8/2004	4/8/2004	4/20/2004	1
47	Yimei Zhou	4/26/2004	4/26/2004	4/26/2004	4/26/2004	5/17/2004	1
48							
49	PI-CHINA						
50	Dr. Fu	4/7/2004	4/7/2004	4/8/2004	4/8/2004	4/14/2004	1
51	Dr. Liang	4/7/2004	4/7/2004	4/8/2004	4/8/2004	4/15/2004	1
52							
53	Others						
54	Glenna Kyle					6/10/2004	1
55	Myron Harrison	3/25/2004	3/25/2004	NA	NA	4/19/2004	1
56	Geoff Granville	6/7/2004	6/7/2004			6/8/2004	1
57							
58	APCO						
59	Laurie Labuda	3/25/2004	3/25/2004	NA	NA	4/15/2004	1
60							
61	API						
62	Lorraine Twerdok	3/25/2004	3/25/2004	NA	NA	4/15/2004	1
63	Paula Podhasky	3/25/2004	3/25/2004	NA	NA		
64	Matt Todd	3/25/2004	3/25/2004	NA	NA		
65	Bruce Jarrot	3/25/2004	3/25/2004	NA	NA	4/15/2004	1
66	Madeleine Sellouk	3/25/2004	3/25/2004	NA	NA		
67	TOTAL						40

Good morning. My name is Patsy Clegg. **I am the Global Product Steward for Shell Chemicals...** and this year I also have the honor of chairing the Oversight Committee of the Benzene Health Research Consortium.

I was happy to see that most everyone arrived in time for dinner last evening, and I hope that you all enjoyed yourselves as much as I did. I had a chance to speak with many of you individually and look forward to more of that during the rest of our stay together.

Along with my industry colleagues from BP, ChevronTexaco, ConocoPhillips, ExxonMobil, and Marathon, it is my sincere pleasure to welcome everyone back to Asilomar and thank you for joining us at this Second Annual Meeting of the Shanghai Health Study. As sponsors of the Study, we appreciate each of you taking the time out of your busy work – and, in some cases, vacation – schedules to be here for this important gathering.

While we have all traveled some distance to be here, I'd like to particularly thank our presenters here today -- many of whom have made the long journey from China to give us an update on their work. It is very good to see the now familiar faces of Professor Fu, Dr. Liang, Dr. Wong, Dr. Schnatter, Tom Armstrong and Dr. Irons. All of you, along with your many colleagues both here and in Shanghai are doing the "hard part" of this work and we truly appreciate your making the trip here to California once again.

In addition, I would like to extend a special welcome to the members of the Scientific Review Panel and the Ethics Review Panel who have joined us this year. With such an august group assembled we are looking forward, once again, to two days of well-informed and well-rounded discussions.

I know that I speak for others as well when I tell you how much I learned from each of you and from all of our panelists last year and I am eager to add to that knowledge base over the next two days.

We have made a great deal of progress over the past twelve months and I believe it is part of our “mission” here at Asilomar to take the time to step back and celebrate our successes.

But, of course there is still much to be done so I hope that we can also take advantage of this opportunity to build on that progress and success, to learn about where the project stands and to gain a bit of insight into the future of this important work.

Last year’s meeting proved to be an invaluable opportunity for us to meet face-to-face to openly exchange information and ideas and ask questions about the progress of the project and the future of the Study.

The extent of the information-sharing, cooperation and mutual respect we have experienced at all levels, has demonstrated the real strength of this effort – the strong collaborative relationships that have developed among the researchers, the Scientific Review Panel, the Ethics Review Panel and the industry sponsors. The strength of these relationships and our mutual commitment to the scientific

work that is underway is an important building block for success and can't be overlooked going forward.

This is an ambitious effort and we've successfully navigated a number of challenges to get where we are today.

Throughout this process, we have learned that by working together and utilizing the scientific and ethical checks and balances that we've put in place we have built a strong foundation for collaboration and success. I am confident that together we can meet any future challenges that may come our way.

We still have a long road ahead of us, but we've passed a number of important milestones together over the past twelve months.

When we met last year, Dr. Irons showed us photographs of the laboratory at Fudan University. The finishing touches were being added to the lab and it was only just beginning to get up and running. In December, we celebrated the launch of the laboratory which is now a fully operational, state-of-the-art diagnostic and clinical facility running at full capacity.

Dr. Irons and Dr. Fu have also worked very hard to establish collaborative relationships between Fudan University and the 27 allied hospitals in Shanghai. This level of cooperation is remarkable and I know Dr. Irons has said he doesn't think it could have been done in the U.S. Their success in bringing these allies together is truly impressive and it is a clear measure of both the importance of the Study and the high esteem to which the medical community in Shanghai holds their work. Likewise, I'd also like to underscore how appreciative we, as sponsors of the study, are to the collaborators in China who have helped to guide us through the various challenges we faced when confronted with the unfamiliar culture and environment in China. We could not have accomplished this on our own.

With the lab facilities up and running and the promise of close collaboration with Shanghai's hospital and medical communities, the study is well underway. We look forward to hearing more from the investigators today about the specifics of their work, the progress that has been made over the past year and what we can look forward to in the months – and even years – ahead.

In industry terms, we've taken big steps forward – from planning through project execution and now to being fully operational. But being “fully operational” does not mean that we can relax and wait for the results to come rolling in, we appreciate that there is much still to be done.

We all know from experience – some of us better than others – that the path to good science isn't always clear and it's almost never quick. We all recognize that this is a multi-year effort and we are committed to seeing it through.

The tranquility of the environment here at Asilomar – without the usual distractions and diversions that most of are used to encountering – made for a very productive and informative meeting last year – something that we hope to replicate again over the next two days.

With the help of the staff and counsel of API we have come together around a fairly ambitious program similar in format to our meeting last year. It is our hope that the plenary sessions will provide a useful framework for all of us to share our experiences and seek and receive support in resolving

any problems from the vast scientific intellect that have gathered here.

Let me thank you once again for joining us, we are all looking forward to a successful two days ahead.

With that in mind, I'm eager to listen and learn so I'd like to introduce our colleague and friend Dr. Patrick Beatty of ChevronTexaco, chair of the Consortium's Technical Committee, who will be our moderator for the day's meeting.

Patrick

Good morning. My name is Patsy Clegg. I am the Product Steward for Shell Chemicals and this year I also have the honor of chairing the Oversight Committee of the Benzene Health Research Consortium.

I was happy to see that most everyone arrived in time for dinner last evening, and I hope that you all enjoyed yourselves as much as I did. I had a chance to speak with many of you individually and look forward to more of that during the rest of our stay together.

Along with my industry colleagues from BP, ChevronTexaco, ConocoPhillips, ExxonMobil, and Marathon, it is my sincere pleasure to welcome everyone back to Asilomar and thank you for joining us at this Second Annual Meeting of the Shanghai Health Study. As sponsors of the Study, we appreciate each of you taking the time out of your busy work – and, in some cases, vacation – schedules to be here for this important gathering. While we have all traveled some distance to be here, I'd like to particularly thank our presenters here today -- many of whom have made the long journey from China to give us an update on their work. It is

good to see the now familiar faces of Professor Fu, Dr. Liang, Dr. Wong, Dr. Schnatter, Tom Armstrong and Dr. Irons. All of you, along with your many colleagues both here and in Shanghai are doing the “hard part” of this work and we truly appreciate your making the trip here to California once again.

In addition, I would like to extend a special welcome to the members of the Scientific Review Panel and the Ethics Review Panel who have joined us this year. With such an august group assembled we are looking forward, once again, to two days of well-informed and well-rounded discussions.

I know that I speak for others as well when I tell you how much I learned from each of you and from all of our panelists last year and I am eager to add to that knowledge base over the next two days.

We have made a great deal of progress over the past twelve months and I believe it is part of our “mission” here at Asilomar to take the time to step back and celebrate our successes.

But, of course there is still much to be done so I hope that we can also take advantage of this opportunity to build on that progress, to learn about where the project stands and to gain a bit of insight into the future of this important work.

Last year's meeting proved to be an invaluable opportunity for us to meet face-to-face to openly exchange information and ideas and ask questions about the progress of the project and the future of the Study.

The extent of the information-sharing, cooperation and mutual respect we have experienced at all levels, has demonstrated the real strength of this effort – the strong relationships and dialogue that have developed among the researchers, the Scientific Review Panel, and the Ethics Review Panel. The strength of these relationships and our mutual commitment to the scientific work that is underway is an important building block for success and can't be overlooked going forward.

This is an ambitious effort and we've successfully navigated a number of challenges to get where we are today.

Throughout this process, we have learned that by working together and utilizing the scientific and ethical checks and balances that we've put in place we have built a strong foundation for collaboration and success. I am confident that together we can meet any future challenges that may come our way.

We still have a long road ahead of us, but we've passed a number of important milestones together over the past twelve months.

When we met last year, Dr. Irons showed us photographs of the laboratory at Fudan University. The finishing touches were being added to the lab and it was only just beginning to get up and running. In December, we formally recognized the launch of the laboratory which is now a fully operational, state-of-the art diagnostic and clinical facility operating at full capacity.

Dr. Irons and Dr. Fu have also worked very hard to establish collaborative relationships between Fudan University and the 27 allied hospitals in Shanghai. This level of cooperation is remarkable and I know Dr. Irons has said he doesn't think it

could have been done in the U.S. Their ability to bring these allies together is truly impressive and it is a clear measure of both the importance of the Study and the high esteem to which the medical community in Shanghai holds their work. Likewise, I'd also like to underscore how appreciative we, as sponsors of the study, are to our collaborators in China who have helped to guide the project through the various challenges presented by the unfamiliar culture and environment in China. We could not have accomplished this on our own.

With the lab facilities up and running and the promise of close collaboration with Shanghai's hospital and medical communities, the study is well underway. We look forward to hearing more from the investigators today about the specifics of their work, the progress that has been made over the past year and what we can look forward to in the months – and even years – ahead.

In industry terms, we've taken big steps forward – from planning through project execution and now to being fully operational. But being “fully operational” does not mean that

we can relax and wait for the results to come rolling in, we appreciate that there is much still to be done.

We all know from experience – some of us better than others – that the path to good science isn't always clear and it's almost never quick. We all recognize that this is a multi-year effort and we are committed to seeing it through. To me, the result we get will be worth the wait. I mentioned earlier that I'm the Product Steward for Shell Chemical. My company, along with the other sponsors of this study, believes that the better we understand the potential effects of exposure to benzene, the better equipped we are to put in place controls to minimize risk. As part of our ongoing commitment to product stewardship, we believe that the insights and understanding we will gain from this study will be important to help ensure that we are effectively managing and minimizing risk.

The tranquil environment at Asilomar – without the usual distractions and diversions that most of are used to encountering – made for a very productive and informative meeting last year – something that we hope to replicate again over the next two days.

With the help of the API staff, we have come together for an ambitious program similar in format to our meeting last year. It is our hope that the plenary sessions will provide a useful framework for all of us to share our experiences and seek and receive support in resolving any problems from the vast scientific intellect that has gathered here.

Let me thank you once again for joining us, we are all looking forward to a productive two days.

With that in mind, I'm eager to listen and learn so I'd like to introduce our colleague and friend Dr. Patrick Beatty of ChevronTexaco, chair of the Consortium's Technical Committee who will be our moderator for the day's meeting.

Patrick....

SHANGHAI HEALTH STUDY

American Petroleum Institute
SHS Administrator
1220 L Street, NW
Washington, DC 20005-4070
Tel: 202-682-8344
Fax: 202-682-8031
E-mail: twerdokl@api.org

January XX, 2005

DRAFT - DRAFT - DRAFT

Name of Individual
Title
Address Line 1
Address Line 2

Dear ----- [SHS Annual Meeting Participant]

The Shanghai Health Study Oversight Committee has been developing preliminary plans for the 2005 Annual Meeting and would like to announce a change of venue for the meeting from Shanghai to Fairfax, Virginia, USA, which is a suburb of Washington, DC.

Dates: Tuesday, November 1 – Thursday, November 3, 2005
Location: ExxonMobil Conference Facilities, Fairfax, Virginia
Hotel: Tysons Corner Ritz Carlton

The meeting would begin with dinner on Tuesday and conclude Thursday. Please hold these dates. *[no para]* The meeting will follow a similar format as previous meetings. Wednesday will be a plenary session where the investigators will present reports on study progress. This will take most of the day to allow time for questions and answers. Thursday will be the opportunity for the Scientific and Ethic Review Panels to meet, both on their own and with the investigators. I want to thank Dr. Fu and his team in China for offering to host our meeting and apologies to all for our change in plans. We look forward to an exciting and successful annual meeting. Agenda, registration and logistical information to be provided as it is developed.

Sincerely,

Patsy Clegg, Product Steward *{need to request preferred titles}*
Chair, Oversight Committee